TVRD logo

Tvardi Therapeutics Inc. (TVRD)

$1.01

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TVRD

Market cap

$13497025

EPS

-0.35

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.363622

Price on TVRD

Previous close

$1.10

Today's open

$1.07

Day's range

$1.01 - $1.08

52 week range

$0.77 - $5.69

Profile about TVRD

CEO

Imran Alibhai

Employees

12

Headquarters

Sugar Land, TX

Exchange

NASDAQ Capital Market

Shares outstanding

13363391

Issue type

Common Stock

TVRD industries and sectors

Healthcare

Biotechnology & Life Sciences

News on TVRD

Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the third quarter ended September 30, 2026, and provided a business update.

news source

GlobeNewsWire • Nov 13, 2026

news preview

Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference

HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan's 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET.

news source

GlobeNewsWire • Oct 14, 2026

news preview

New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)

In a preclinical chronic colitis model, Tvardi's oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3-driven disease biology  Collective findings now span multiple preclinical models of UC, further supporting the scientific rationale for advancing TTI-109, Tvardi's next-generation STAT3 inhibitor, in UC HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced the publication of preclinical data evaluating Tvardi's STAT3 inhibitor in the International Journal of Molecular Sciences.

news source

GlobeNewsWire • Sep 24, 2026

news preview

Tvardi Therapeutics to Participate in Upcoming Investor Events

HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:

news source

GlobeNewsWire • Aug 26, 2026

news preview

Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript

Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript

news source

Seeking Alpha • Aug 19, 2026

news preview

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Reported topline healthy volunteer  results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations

news source

GlobeNewsWire • Aug 14, 2026

news preview

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that it will host a KOL webinar on Wednesday, August 19, 2026 at 11:00 AM ET featuring Randy Longman, MD, PhD (Weill Cornell Medicine), who will join Tvardi management to discuss the current treatment landscape in ulcerative colitis (UC) and the persistent unmet needs that remain despite recent clinical advances and currently approved therapies. The event will feature new data from Tvardi and a review of the Phase 1 healthy volunteer results supporting the potential of TTI-109 in UC.

news source

GlobeNewsWire • Aug 12, 2026

news preview

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

news source

GlobeNewsWire • Jul 30, 2026

news preview

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.

news source

Zacks Investment Research • Jul 9, 2026

news preview

Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript

Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript

news source

Seeking Alpha • Jul 7, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Tvardi Therapeutics Inc.

Open an M1 investment account to buy and sell Tvardi Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TVRD on M1